Metabolic, neurological and endocrine safety profiles of atypical antipsychotics: focus on quetiapine, olanzapine and risperidone: an updated review
DOI:
https://doi.org/10.18203/2320-6012.ijrms20260997Keywords:
Endocrine effects, Metabolic syndrome, Microbiota, Neurological safety, Olanzapine, Quetiapine, RisperidoneAbstract
The atypical antipsychotics (second-generation antipsychotics, SGAs) are commonly used in the treatment of schizophrenia, bipolar disorder and other mental illnesses because they have fewer extrapyramidal side effects than first-generation agents. Nonetheless, their growing utilization has brought to light serious safety issues, especially in metabolic, neurological and endocrine spheres. This review aims at comparing three widely used SGAs, which are Quetiapine, Olanzapine, and Risperidone, with comparison in their pharmacological and safety profiles. Olanzapine presents the greatest metabolic risk often leading to weight gain, dyslipidaemia and insulin resistance. Quetiapine exhibits less sensitive metabolic responses accompanied by reduced pyramidal and prolactin increase rates at low off-label doses but is risky. Risperidone is an effective treatment of psychotic and bipolar disorders, but it is closely linked to hyperprolactinemia and dose-related extrapyramidal symptoms. The review also points out that there is now emerging evidence on changes in gut microbiota and changes in pharmacogenetic variations that affect individual response to drug and drug adverse effects. In general, the results highlight the importance of identifying unique antipsychotic treatment, regular checks of metabolic, endocrine indicators to ensure optimal safety and treatment. It is recommendable that future studies concentrate on genetic predictors, new formulations (e.g. olanzapine-samidorphan), and microbiome-targeted interventions as a way of reducing adverse effects.
Metrics
References
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77. DOI: https://doi.org/10.1016/S2215-0366(19)30416-X
Modesto-Lowe V, Harabasz AK, Walker SA. Quetiapine for primary insomnia: Consider the risks. Cleve Clin J Med. 2021;88(5):286-94. DOI: https://doi.org/10.3949/ccjm.88a.20031
Libowitz MR, Nurmi EL. The burden of Antipsychotic-Induced Weight gain and Metabolic Syndrome in children. Front Psychiatry. 2021;12:623681. DOI: https://doi.org/10.3389/fpsyt.2021.623681
Alsabhan JF, Backer NBA, Hassan FM, Albaker AB, Assiry G. Metabolic Side Effects of Risperidone in Pediatric Patients with Neurological Disorders: A Prospective Cohort Study. J Clin Med. 2024;13(18):5565. DOI: https://doi.org/10.3390/jcm13185565
Burghardt KJ, Seyoum B, Mallisho A, Burghardt PR, Kowluru RA, Yi Z. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog neuro-psychopharmacol biol psychiatry. 2018;83:55-63. DOI: https://doi.org/10.1016/j.pnpbp.2018.01.004
Willner K, Vasan S, Patel P, Rajan A, Madaan V. Atypical Antipsychotic Agents. Treasure Island (FL): StatPearls Publishing. 2025. Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK448156/. Accessed on 07 January 2026.
Frond D, Rettig A, Burghardt K. Epigenetic insights of olanzapine-induced insulin resistance. Epigenomics. 2025;17(8):507-9. DOI: https://doi.org/10.1080/17501911.2025.2489341
Spelber D, Almeida J, Nemeroff CB. Bipolar disorder. Comprehensive pharmacology. 2022;325-50. DOI: https://doi.org/10.1016/B978-0-12-820472-6.00019-0
Stojkovic M, Radmanovic B, Jovanovic M, Janjic V, Muric N, Ristic DI. Risperidone Induced Hyperprolactinemia: From Basic to Clinical Studies. Front psychiatry. 2022;13:874705. DOI: https://doi.org/10.3389/fpsyt.2022.874705
Sonim P, Ferreira RM, Lourenço I, Fernandes L, Ferreira AR. Metabolic Adverse Effects of Low-Dose Quetiapine: A Systematic Review and Meta-Analysis. Acta psychiatr Scand. 2025. DOI: https://doi.org/10.1111/ACPS.70023/v3/response1
Bak M, Fransen A, Janssen J, van OS, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PloS one. 2014;9(4):e94112. DOI: https://doi.org/10.1371/journal.pone.0094112
Messer T, Bernardo M, Anta L, Martínez-González J. Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia. Ther adv psychopharmacol. 2024;14:20451253241280046. DOI: https://doi.org/10.1177/20451253241280046
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5): 957-70. DOI: https://doi.org/10.1038/sj.npp.1301492
Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health affairs. 2009;28(5):w770-81. DOI: https://doi.org/10.1377/hlthaff.28.5.w770
Ayano G. Second generation antipsychotics: Pharmacodynamics, therapeutic effects, indications and associated metabolic side effects: Review of articles. J Schizophr Res. 2016;3(2):1027.
Thomas K, Saadabadi A. Olanzapine. Treasure Island (FL): StatPearls Publishing. 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532903/. Accessed on 07 January 2026.
Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions. Pharmacogenomics and personalized medicine. 2023;16:1097-108. DOI: https://doi.org/10.2147/PGPM.S391401
Maan JS, Ershadi M, Khan I, Singh R. Quetiapine. [Treasure Island (FL): StatPearls Publishing. 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459145/. Accessed on 07 January 2026.
Food and Drug Administration. Seroquel (quetiapine fumarate) prescribing information. U.S. Department of Health and Human Services. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020639s061lbl.pdf. Accessed on 07 January 2026.
Zubiaur P, Soria-Chacartegui P, Villapalos-García G, Gordillo-Perdomo JJ, Abad-Santos F. The pharmacogenetics of treatment with olanzapine. Pharmacogenomics. 2021;22(14):939-58. DOI: https://doi.org/10.2217/pgs-2021-0051
McNeil SE, Gibbons JR, Cogburn M. Risperidone. StatPearls - NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459313/. Accessed on 07 January 2026.
Joshi K, Rao S, Mehta S. A review of pharmacokinetic and pharmacodynamic properties of quetiapine ir and xr: Insights and clinical practice implications. Cureus. 2025. DOI: https://doi.org/10.7759/cureus.86258
Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin. 2013;29(7):813-25. DOI: https://doi.org/10.1185/03007995.2013.794774
Uttreja P, Youssef AAA, Karnik I, Sanil K, Narala N, Wang H, et al. Formulation Development of solid Self-Nanoemulsifying drug delivery systems of quetiapine fumarate via Hot-Melt extrusion technology: optimization using central composite design. Pharmaceutics. 2024;16(3):324. DOI: https://doi.org/10.3390/pharmaceutics16030324
Bushe CJ, Falk D, Anand E, Casillas M, Perrin E, Chhabra-Khanna R, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry. 2015;15(1):1-10. DOI: https://doi.org/10.1186/s12888-015-0450-9
Rehan ST, Siddiqui AH, Khan Z, Imran L, Syed AA, Tahir MJ. Samidorphan/olanzapine combination therapy for schizophrenia: Efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg. 2022;79:104073. DOI: https://doi.org/10.1016/j.amsu.2022.104115
Turk T, Alkhatib M, Abbas G, Jawish MK, Alshar OMH, Alchamat HA, et al. Risperidone (oral forms) for people with schizophrenia. Cochrane Database Syst Rev. 2017;CD008428. DOI: https://doi.org/10.1002/14651858.CD012822
Khan M, Manalai N, Osmani GP, Foroobar A, Harrison P, Scercy C, et al. A practical guide to prescribing long-acting injectable medications: Clinically informed technological aspects and algorithmic approaches for enhanced understanding and implementation in clinical practice. Int J Res Med Sci. 2025;7(1):12-23. DOI: https://doi.org/10.33545/26648733.2025.v7.i1a.83
Lopez LV, Kane JM. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. J Clin Psychiatry. 2015;76(9):1249-50. DOI: https://doi.org/10.4088/JCP.15ac10243
Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2005;61(1):58-69. DOI: https://doi.org/10.1111/j.1365-2125.2005.02507.x
Curry DE, Richards BL. A brief review of Quetiapine. Am J Psychiatry Residents J. 2022;18(2):20-2. DOI: https://doi.org/10.1176/appi.ajp-rj.2022.180207
Chopra N, Ruan C, McCollum B, Ognibene J, Shelton C, De Leon J. High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers. Revista Colombiana De Psiquiatría. 2018;49(2):84-95. DOI: https://doi.org/10.1016/j.rcp.2018.07.002
Gardner A. 10 benefits of grapefruit, plus facts and nutrition. Health. 2025. Available at: https://www.health.com/food/grapefruit-facts. Accessed on 07 January 2026.
Daemen MJ. The heart and the brain: an intimate and underestimated relation. Netherlands Heart Journal. 2013;21(2):53-4. DOI: https://doi.org/10.1007/s12471-012-0371-x
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341-56. DOI: https://doi.org/10.1002/wps.20567
Surineni K, Smith A, Glein R, Schrader N. A Case of Olanzapine Resistance from Heavy Smoking and Clinical Considerations. Kansas Journal of Medicine.2025;18(1):21-2. DOI: https://doi.org/10.17161/kjm.vol18.22846
Lucas C, Martin J. Smoking and drug interactions. Australian Prescriber. 2013;36(3):102-4. DOI: https://doi.org/10.18773/austprescr.2013.037
Spina E, Barbieri MA, Cicala G, De Leon J. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals. 2020;13(12):439. DOI: https://doi.org/10.3390/ph13120439
Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: The effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014;4(3):e004216. DOI: https://doi.org/10.1136/bmjopen-2013-004216
Oshikoya KA, Neely KM, Carroll RJ, Aka IT, Maxwell-Horn AC, Roden DM, et al. CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res. 2019;85(5):602-6. DOI: https://doi.org/10.1038/s41390-019-0305-z
Dean L. Risperidone Therapy and CYP2D6 Genotype. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US). 2012. Available at: https://www.ncbi.nlm.nih.gov/books/NBK425795/?utm. Accessed on 07 January 2026.
Zhang L, Brown SJ, Shan Y, Lee AM, Allen JD, Eum S, et al. CYP2D6 genetic polymorphisms and risperidone pharmacokinetics: A systematic review and meta‐analysis. Pharmacotherapy. 2020;40(7):632-47. DOI: https://doi.org/10.1002/phar.2434
Dodsworth T, Kim DD, Procyshyn RM, Tse LT, Pang CN. A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health. 2018;12:37. DOI: https://doi.org/10.1186/s13034-018-0243-2
Huang J, Hei GR, Yang Y, Liu CC, Xiao JM, Long YJ, et al. Increased appetite plays a key role in olanzapine-induced weight gain in first-episode schizophrenia patients. Front Pharmacol. 2020;11:739. DOI: https://doi.org/10.3389/fphar.2020.00878
Li H, Peng S, Li S, Liu S, Lv Y, Yang N, et al. Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance. Sci Rep. 2019;9(1). DOI: https://doi.org/10.1038/s41598-018-36930-y
AstraZeneca. Highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020639s061lbl.pdf. Accessed on 07 January 2026.
Wu CY, Mitchell SR, Seyfried LS. Quetiapine-induced hyperglycemic crisis and severe hyperlipidemia: A case report and review of the literature. Psychosomatics. 2014;55(6):686-91. DOI: https://doi.org/10.1016/j.psym.2014.07.002
Correll CU. Olanzapine/Samidorphan Effects on Weight Gain: An Individual patient Data Meta-Analysis of Phase 2 and 3 Randomized Double-Blind Studies. Psychiatrist.com. Available at: https://www.psychiatrist.com/jcp/olanzapine-samidorphan-effects-weight-gain-meta-analysis-of-phase-2-and-3-randomized-double-blind-studies. Accessed on 07 January 2026.
Koricanac A, Tomic Lucic A, Veselinovic M, Bazic Sretenovic D, Bucic G, Azanjac A, et al. Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia. Front psychiatry. 2022;13:925757. DOI: https://doi.org/10.3389/fpsyt.2022.925757
Paray AA, Mir MA, Chandra M, Yousuf A, Singh M. Microbes matter: A review on the current update on gut microbiota in relation to autism. Int J Pharm Sci Res. 2025;16(2):345-53.
Bretler T, Weisberg H, Koren O, Neuman H. The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. BMC Med. 2019;17(1):112. DOI: https://doi.org/10.1186/s12916-019-1346-1
Seeman MV. What is the significance of the impact of antipsychotics on the gut microbiome?. Expert Rev Neurother. 2023;23(2):125-7. DOI: https://doi.org/10.1080/17425255.2023.2200161
Li X, Yuan X, Pang L, Miao Y, Wang S, Zhang X, et al. Gut microbiota markers for antipsychotics induced metabolic disturbance in drug naïve patients with first episode schizophrenia – A 24 weeks follow-up study. medRxiv. 2020. DOI: https://doi.org/10.1101/2020.12.26.20248886
Pan LY, Zhou YY, Zhang X, Jiang HY. Gut microbiota is associated with weight gain in children treated with atypical antipsychotic: A pilot longitudinal study. Psychiatry Res. 2022;316:114784. DOI: https://doi.org/10.1016/j.psychres.2022.114784
Dias MF, Nogueira YJA, Romano‑Silva MA, Marques de Miranda D. Effects of antipsychotics on the gastrointestinal microbiota: A systematic review. Psychiatry res. 2024;336:115914. DOI: https://doi.org/10.1016/j.psychres.2024.115914
Cheng W, Zhao M, Zhang X, Zhou X, Yan J, Li R, et al. Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis. Schizophr Res. 2024 ;274:257-68. DOI: https://doi.org/10.1016/j.schres.2024.07.053
Lu Q, Lai J, Lu H, Ng C, Huang T, Zhang H, et al. Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: An Advanced Exploration. Front Psychiatry. 2019;10:784. DOI: https://doi.org/10.3389/fpsyt.2019.00784
Dere W, Suto T. The role of pharmacogenetics and pharmacogenomics in improving translational medicine. Clin Cases Miner Bone Metab. 2009;6:13-6.
Yoshida K, Müller DJ. Pharmacogenetics of antipsychotic drug treatment: Update and clinical implications. Mol Neuropsychiatry. 2020;5(1):1-26. DOI: https://doi.org/10.1159/000492332
Vasiliu O. The pharmacogenetics of the new-generation antipsychotics - a scoping review focused on patients with severe psychiatric disorders. Front Psychiatry. 2023;14:1124796. DOI: https://doi.org/10.3389/fpsyt.2023.1124796
Carrascal-Laso L, Isidoro-García M, Ramos-Gallego I, Franco-Martín MA. Review: Influence of the CYP450 genetic variation on the treatment of psychotic disorders. J Clin Med. 2021;10(18):4275. DOI: https://doi.org/10.3390/jcm10184275
Liu K, Zhang B, Chen Z, Chen F, Li Z, et al. Efficacy of atypical antipsychotics in schizophrenia patients: effects of 5-HTR SNPs. Ann Gen Psychiatry. 2025;24(1):10. DOI: https://doi.org/10.1186/s12991-025-00547-z
Ortega-Ruiz M, Soria-Chacartegui P, Villapalos-García G, Abad-Santos F, Zubiaur P. The pharmacogenetics of treatment with quetiapine. Future Pharmacol. 2022;2(3):276-86. DOI: https://doi.org/10.3390/futurepharmacol2030018
Laika B, Leucht S, Heres S, Schneider H, Steimer W. Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J. 2010;10(1):20-9. DOI: https://doi.org/10.1038/tpj.2009.32
Hattori S, Suda A, Miyauchi M, Shiraishi Y, Saeki T, Fukushima T, et al. The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine. BMC Psychiatry. 2020;20:72. DOI: https://doi.org/10.1186/s12888-020-02492-5
Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin Drug Metab Toxicol. 2022;18(11):769-85. DOI: https://doi.org/10.1080/17425255.2022.2160317
Annotation of DPWG Guideline for Quetiapine and CYP3A4, PharmGKB. 2025. Available at: https://www.pharmgkb.org/guidelineAnnotation/PA166265421. Accessed on 07 January 2026.
Downloads
Published
How to Cite
Issue
Section
